Status
Conditions
About
The purpose of this observational study is to understand the causes of pleural effusion (a buildup of fluid around the lungs) in patients with advanced Chronic Kidney Disease (CKD Stages 3 to 5). Pleural effusion is a common complication in kidney disease, but it can be caused by many different issues, such as simple fluid overload, heart failure, or infections like tuberculosis.
To treat this fluid buildup effectively, doctors need to classify whether the fluid is a transudate (usually caused by pressure imbalances like fluid overload) or an exudate (caused by inflammation, lung disease, or infection). Standard medical formulas, known as Light's Criteria, are typically used to figure this out by comparing proteins in the fluid to proteins in the blood. However, these standard tests may sometimes misclassify the fluid in kidney disease patients because their baseline blood protein and albumin levels are often altered by their condition.
Researchers in this study will enroll adult CKD patients (both on dialysis and not yet on dialysis) who have confirmed fluid around their lungs. Participants will undergo a standard, ultrasound-guided procedure called a diagnostic thoracentesis to safely draw a small amount of the chest fluid. At the same time, a routine blood sample will be taken.
The study aims to:
Full description
Chronic kidney disease (CKD) is a major global health burden. As CKD progresses through stages III-V, systemic complications become increasingly prevalent, with pleural effusion identified in 20-40% of CKD patients at autopsy. Pleural effusion in CKD arises from diverse mechanisms. Transudative effusions are predominantly associated with fluid overload and heart failure. Exudative effusions are most commonly caused by tuberculosis, uremic pleuritis, and parapneumonic processes.
The cornerstone of differentiating transudative from exudative pleural effusions remains Light's Criteria. However, the criteria carry an acknowledged risk of misclassification in CKD patients, where altered protein metabolism, reduced serum albumin, and dialysis-related biochemical shifts may distort pleural fluid-serum ratios. Given the diagnostic complexity posed by coexisting comorbidities, there is a clear need for a dedicated prospective study that systematically evaluates the incidence, etiology, and biochemical classification of pleural effusions in CKD Stage 3-5 patients.
Eligible participants will undergo a comprehensive clinical evaluation, which includes a structured clinical history form to capture demographic data, presenting symptoms, CKD history, dialysis status, and comorbidities. A physical examination will assess signs of fluid overload and pleural effusion findings.
Imaging studies will be utilized to confirm and grade the effusion. This includes a Chest X-ray (PA view) as an initial screening tool and Thoracic Ultrasound to assess effusion volume, echogenicity, and loculation. A CT Chest may be performed if ultrasound or X-ray findings are inconclusive, or if malignancy or complicated effusion is suspected.
A diagnostic thoracentesis will be performed under full aseptic conditions and ultrasound guidance to minimize complications. Approximately 30-60 mL of pleural fluid will be aspirated for diagnostic analysis, which includes gross appearance, total protein, LDH, glucose, pH, albumin, cell count, Gram stain, AFB smear, and cytology. Simultaneous serum laboratory tests will be collected at the same time as the thoracentesis for ratio calculations.
To evaluate diagnostic accuracy in the CKD population, four classification methods will be applied to each patient's samples:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
100 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal